Key takeaways
- ARA-290 is an investigational peptide with no FDA-approved label or indication.
- It is registered in a small number of clinical trials, four in total.
- Sample trials have looked at cognitive and neural effects, diabetic macular oedema, and corneal nerve and neuropathic symptoms in sarcoidosis.
- One of the sampled trials was terminated and two are listed as completed.
- No adverse event reporting data is currently available for this compound.
What ARA-290 is
ARA-290 is a synthetic peptide identified in chemical databases under PubChem CID 91810664, with a molecular formula of C51H84N16O21 and a molecular weight of about 1,257 daltons. It has not been reviewed or approved by any regulatory agency, and no official drug label exists for it. Any use of ARA-290 outside of registered research settings falls outside an established medical framework.
Trial footprint
Four clinical trials involving ARA-290 are currently registered. Among the sampled studies, one examined cognitive and neural effects of the compound and was completed. Another looked at corneal nerve fiber density and neuropathic symptoms in people with sarcoidosis and was also completed. A third trial, studying ARA-290 for diabetic macular oedema, was terminated before completion. These records describe study activity only and do not indicate whether ARA-290 is safe or effective for any use.